Table 2.

Characteristics of primary AML specimens

All patients (n = 27)aNewly diagnosed AML (n = 15)Relapsed/refractory AML (n = 12)
Median age (range), years58.1 (23.9–76.2)64.0 (40.2–76.2)44.4 (23.9–67.4)
Cytogenetic/molecular risk
 Favorable22
 Intermediate18108
  CEBPAdouble-mutant11
  NPM1pos/FLT3-ITDneg11
  NPM1pos/FLT3-ITDpos or NPM1neg/FLT3-ITDpos1055
 Adverse734
Specimen source
 Bone marrow1147
 Peripheral blood16115
Median % blasts (range)86.1 (58.4–97.0)86.1 (66.7–95.5)86.7 (58.4–97.0)
Median CD33 expression on blasts (range)b849 (5–5,356)849 (5–5,356)788 (7–2,242)
Median % T cells (range)2.0 (0–11.9)1.6 (0–11.9)2.1 (0.7–8.7)
Median % viability at 48 hours (range)80.1 (53.6–93.6)76.0 (53.6–93.6)83.5 (63.9–93.1)
  • aOnly specimens with >50% viability at completion of experiments are described.

  • bMean fluorescence intensities